Dori Pharmaceuticals rose by the daily limit and closed at 48.83 yuan. The stock rose by the daily limit at 13:59, but did not open the limit. The closing capital was 36.4308 million yuan, accounting for 3.73% of its current market value.
In terms of capital flow data, the net inflow of main funds on the same day was 80.5192 million yuan, the net inflow of hot capital was 42.7004 million yuan, and the net outflow of retail funds was 50.82 million yuan. The flow of funds in the past five days is shown in the following table:
The stock is a hot stock of pharmaceutical concepts, which rose 1.29% on the day.
The investment logic of the stock is as follows:
1. The company is mainly engaged in the research, production and marketing of chemical preparations and their raw materials; it focuses on the layout of product pipelines in the field of perioperative and emergency rescue, and has achieved a strong competitive advantage in the subdivision of plasma substitutes; the core product Sodium Acetate Ringer injection is the first imitation drug in China through independent research and development.
From the perspective of financial situation, the third quarterly report of Dori Pharmaceutical 2021 showed that the company's main income was 396 million yuan, up 19.73% from the same period last year; the net profit was 49.3443 million yuan, down 18.68% from the same period last year; deducting 45.1715 million yuan from non-net profit, of which in the third quarter of 2021, the company's main income in a single quarter was 152 million yuan, down 1.63% from the same period last year; and the net profit in a single quarter was 12.2716 million yuan, down 14.83% from the same period last year. In a single quarter, the non-net profit is 12.1634 million yuan, the debt ratio is 12.67%, the financial expenses are 1.0716 million yuan, and the gross profit margin is 89.94%.
According to the Securities Star valuation analysis tool, Dori Pharmaceuticals (301075) has a rating of 4 stars, a good price rating of 0.5 stars, and a comprehensive valuation rating of 2 stars. The stock has no agency rating in the last 90 days. In the past three months, the net inflow of financing was 7.4871 million, and the financing balance increased, while the net inflow of securities was 0, and the balance of securities lending increased.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.